List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
27 September 2010 | By AstraZeneca
AstraZeneca announced that a study evaluating zibotentan for the treatment of men with metastatic CRPC did not show improvement in the primary endpoint of overall survival...
24 September 2010 | By AstraZeneca
AstraZeneca announced that the CHMP issued a positive opinion on the marketing authorisation...
10 September 2010 | By NG Online News
Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
2 September 2010 | By AstraZeneca
AstraZeneca announced that the EC issued a decision for the approval of SEROQUEL XR...
19 August 2010 | By David Cook, Associate Director, Global Safety Assessment, AstraZeneca
Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction which accounts for a significant amount of patient suffering, including death. Currently, idiosyncratic DILI is unpredictable and as a result arises late in the drug development process or even post-marketing. The prediction of idiosyncratic DILI based on preclinical or…
9 August 2010 | By AstraZeneca
AstraZeneca reached agreements in principle with attorneys representing approx 17,500 SEROQUEL product liability claimants...
29 July 2010 | By AstraZeneca
AstraZeneca today announced that Dr Bruce Burlington is to join the Board of Directors as a Non-Executive Director, with effect from 1 August 2010...
26 July 2010 | By AstraZeneca
The FDA posted briefing materials in advance of 28th July 2010 CRDAC to discuss the New Drug Application (NDA) filed by AstraZeneca...
21 July 2010 | By NG Online News
Back in May, it was announced that new stem cell research would reduce the need for animal testing...
5 July 2010 | By AstraZeneca
AstraZeneca and MRC Technology, announced a new strategic collaboration to share access to...
2 July 2010 | By NG Online News
The pharmaceutical industry has faced well documented challenges over the last 12 months, such as the Pfizer...
BGMA welcomes EU General Court ruling that AstraZeneca abused its dominant position by preventing the marketing of generic omeprazole.
30 June 2010 | By AstraZeneca
AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the ‘314 patent) is valid and enforceable...
28 June 2010 | By AstraZeneca
AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria...
25 June 2010 | By Peter Alcock, Colin Bath, Carolyn Blackett & Peter B. Simpson, Screening & Assay Sciences, Cancer Bioscience, AstraZeneca Alderley Park
Over the last 15 years, vendors have offered microscope-based instruments capable of producing images of fluorescent labelled components of cells grown in microtitre plates. These instruments are typically bundled with analysis software capable of defining the relative distribution of several fluorescent markers on a cell by cell basis1,2. As the…
